Search results
Neurocrine Biosciences, Inc. [NBIX] Investment Appeal on the Rise – Knox Daily
Knox Daily· 1 day agoAs a result of the transaction, Delaet Ingrid now holds 7,507 shares, worth roughly $1.07 million. Wells Fargo upgraded its Neurocrine Biosciences, Inc. [NBIX] rating to an ...
BMO Capital Markets Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $138.00
ETF DAILY NEWS· 3 days agoNeurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target increased by BMO Capital Markets from $129.00 to $138.00 in a research report report published on Thursday ...
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Tehachapi News· 2 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of...
NBC 10 - FOX 14 Monroe· 22 hours agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 hours agoNxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical ...
Neurocrine shares target lifted on neurocrine developments By Investing.com
Investing.com· 7 days agoOn Thursday, H.C. Wainwright adjusted its price target for shares of Neurocrine (NASDAQ:NBIX)...
Neurocrine Biosciences, Inc. (NBIX): Worth Consideration At $140.71 – Stocks Register
Stocks Register· 5 days agoNeurocrine Biosciences, Inc. (NASDAQ:NBIX) concluded the trading at $140.71 on Friday, May 03, with a rise of 0.63% from its closing price on previous day. Taking a look at ...
Q2 2024 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Decreased by Analyst
ETF DAILY NEWS· 2 days agoNeurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Stock analysts at Wedbush dropped their Q2 2024 earnings per share estimates for shares of Neurocrine Biosciences ...
Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
Simply Wall St. via Yahoo Finance· 7 days agoNeurocrine Biosciences (NASDAQ:NBIX) First Quarter 2024 Results Key Financial Results Revenue:...
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program...
WDTN-TV 2 Dayton· 2 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data ...